Santen Pharmaceutical Co., Ltd.

Tokyo Stock Exchange:4536.T

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

💊 Drugstores & Retail Pharmacies

🕶 Eyewear

💊 Pharmaceuticals

Location

Japan

Market Cap

USD 3.95 B

Share Price

USD 11.58

Avg Daily Volume

1,274,321

Change (1 day)

-0.07%

Change (1 year)

13.89%

Change (YTD)

12.31%

Santen Pharmaceutical Co., Ltd. Depreciation And Amortization for the year ending March 31, 2025: USD 119.64 M

Santen Pharmaceutical Co., Ltd. Depreciation And Amortization is USD 119.64 M for the year ending March 31, 2025, a -0.38% change year over year. Depreciation and amortization are expense that reduces the value of tangible and intangible assets over their useful lives for tax and reporting purposes.

Santen Pharmaceutical Co., Ltd. Depreciation And Amortization for the year ending March 31, 2024 was USD 120.10 M, a -7.50% change year over year.
Santen Pharmaceutical Co., Ltd. Depreciation And Amortization for the year ending March 31, 2023 was USD 129.83 M, a -7.33% change year over year.
Santen Pharmaceutical Co., Ltd. Depreciation And Amortization for the year ending March 31, 2022 was USD 140.11 M, a -7.47% change year over year.
Santen Pharmaceutical Co., Ltd. Depreciation And Amortization for the year ending March 31, 2021 was USD 151.42 M, a -1.75% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Depreciation And Amortization	Dividends Paid	Common Stock Issued	Common Stock Repurchased

Tokyo Stock Exchange: 4536.T

Santen Pharmaceutical Co., Ltd.

CEO	Mr. Takeshi Ito
IPO Date	Jan. 4, 2001
Location	Japan
Headquarters	Grand Front Osaka Tower A
Employees	3,744
Sector	🏥 Health Care
Industries Clinical Trials 💊 Drugstores & Retail Pharmacies 🕶 Eyewear 💊 Pharmaceuticals

Description

Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products to treat glaucoma and ocular hypertension, such as DE-111, which is in Phase III clinical trial; DE-117 in Japan; DE-126 that is in Phase IIb clinical trial; DE-128 in Europe, as well as is in Phase II/III clinical trial in the United States; and DE-130A that is in Phase III clinical trial. In addition, the company provides DE-114A to treat allergic conjunctivitis; DE-076C for the treatment of vernal keratoconjunctivitis; and DE-109, which is in Phase III clinical trial to treat uveitis. Further, it offers DE-127 to treat myopia, which is in Phase II/III clinical trial in Japan, as well as is in Phase III in Asia; DE-089C, which has completed Phase III clinical trials for the treatment of dry eye; and STN1013400, which is in Phase I clinical trials for the treatment of myopia. Additionally, the company offers over-the-counter pharmaceutical products. The company was formerly known as Santendo Pharmaceutical Co., Ltd. and changed its name to Santen Pharmaceutical Co., Ltd. in 1958. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan.